Literature DB >> 2644571

The kallikrein-kinin and renin-angiotensin systems in nephrotic syndrome.

A D Cumming1, S Jeffrey, A T Lambie, J S Robson.   

Abstract

We previously found that virtually all patients with nephrotic syndrome (NS) excrete supranormal amounts of urinary kallikrein; it is known that activity of the renin-angiotensin system (RAS) is increased in some such patients. We therefore studied the relationship between urinary kallikrein excretion (UKa) and plasma renin activity (PRA) in 16 patients with NS. Compared with healthy controls, PRA was normal in 8 subjects and elevated in 8; UKa was elevated in the high-renin group (40.4 +/- 5.2 nkat/24 h, normals 12.0 +/- 1.1). UKa was also elevated in the normal renin group (25.7 +/- 2.4 nkat/24 h) but to a significantly lesser degree. Significant activity in plasma against a specific substrate of glandular and renal kallikreins was observed in 8 of 10 patients with NS. Such activity was not found in plasma of 17 patients with glomerulonephritis without NS, or in 10 healthy controls. The results are in keeping with previous suggestions of a functional link between the renal kallikrein-kinin system (KKS) and the RAS, but indicate that the renal KKS is activated in NS, in some cases independently of the RAS. It is possible that renal kallikrein reaches the systemic circulation in some patients with NS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644571     DOI: 10.1159/000185283

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

Review 1.  Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension.

Authors:  Evan C Ray; Helbert Rondon-Berrios; Cary R Boyd; Thomas R Kleyman
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

2.  Risk factors and clinical characteristics of tacrolimus-induced acute nephrotoxicity in children with nephrotic syndrome: a retrospective case-control study.

Authors:  Ping Gao; Xin-Lei Guan; Rui Huang; Xiao-Fang Shang-Guan; Jiang-Wei Luan; Mao-Chang Liu; Hua Xu; Xiao-Wen Wang
Journal:  Eur J Clin Pharmacol       Date:  2019-11-19       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.